睿知中国医院研究地图
候选清单

正在招募乳腺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 2

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
  2. 研究中心中山大学孙逸仙纪念医院Sun Yat-sen Memorial Hospital广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06957886,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:仅女性

    登记记录的入选字段

  2. Histologically or cytologically confirmed unresectable, locally recurrent or metastatic HER2-low breast cancer;

    入选标准第 4 条

  3. Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0;

    入选标准第 9 条

    Received mitomycin C and nitrosourea chemotherapy within 6 weeks before the first dose, and received surgery or radical radiotherapy within 4 weeks before the first dose;

    排除标准第 1 条

    Previous treatment with anti-HER2 drugs;

    排除标准第 3 条

  4. ECOG 0 or 1;

    入选标准第 8 条

  5. Must have at least one measurable target lesion that meets the RECIST v1.1 definition;

    入选标准第 7 条

  6. Other primary malignancies diagnosed within 5 years before the first dose;

    排除标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06957886,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntarily sign the informed consent and follow the requirements of the protocol;
  2. Women aged ≥18 years and ≤75 years at the time of written informed consent;
  3. Expected survival time ≥12 weeks;
  4. Histologically or cytologically confirmed unresectable, locally recurrent or metastatic HER2-low breast cancer;
  5. Provide the latest tumor tissues to the central laboratory for HER2 and HR detection;
  6. Meet the treatment requirements in the plan;
  7. Must have at least one measurable target lesion that meets the RECIST v1.1 definition;
  8. ECOG 0 or 1;
  9. Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0;
  10. Organ function level must meet the requirements;
  11. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and must be non-lactating; All enrolled patients (male or female) should use adequate, highly effective contraception for the entire treatment cycle and for 7 months after completion of treatment.

排除标准:Exclusion Criteria:

  1. Received mitomycin C and nitrosourea chemotherapy within 6 weeks before the first dose, and received surgery or radical radiotherapy within 4 weeks before the first dose;
  2. Patients who were not suitable to use the control drugs chosen by the researchers because of intolerance to the chemotherapy drugs of the control group or other contraindications;
  3. Previous treatment with anti-HER2 drugs;
  4. Prior ADC drug therapy with camptothecin derivative as toxin;
  5. The history of severe cardiovascular and cerebrovascular diseases in the past six months was screened;
  6. Severe impairment of lung function due to concurrent pulmonary diseases;
  7. History of ILD/interstitial pneumonia requiring steroid therapy, current ILD/interstitial pneumonia or suspected ILD/interstitial pneumonia;
  8. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
  9. Other primary malignancies diagnosed within 5 years before the first dose;
  10. Poorly controlled hypertension;
  11. Patients with active central nervous system metastases;
  12. Patients with a history of severe allergy to any excipients or components of the study drug;
  13. History of autologous or allogeneic stem cell transplantation or organ transplantation;
  14. Anthracycline-equivalent cumulative dose of adriamycin > 360 mg/m2;
  15. Human immunodeficiency virus antibody positive, active hepatitis B virus infection, cirrhosis, or hepatitis C virus infection;
  16. Serious infection within 4 weeks before the first dose of study drug; Severe infection requiring antibiotic, antiviral or antifungal control at screening;
  17. Patients with massive effusions, or effusions with obvious symptoms, or poorly controlled effusions;
  18. Carcinomatous lymphangitis;
  19. Was receiving \&gt before randomization; 10mg/d prednisone systemic corticosteroids or equivalent anti-inflammatory active drugs or any form of immunosuppressive therapy;
  20. The presence of a severe neurological or mental illness;
  21. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
  22. Intestinal obstruction, Crohn's disease, ulcerative colitis or chronic diarrhea;
  23. Subjects who are scheduled to receive live vaccine or receive live vaccine within 28 days before the first dose;
  24. Patients with other serious physical or laboratory abnormalities or poor compliance that may increase the risk of participating in the study or interfere with the results of the study, and patients who are considered by the investigators to be unsuitable for participating in the study.

引自 ClinicalTrials.gov, NCT06957886, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06957886,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06957886